CYP450 and drug efflux transporters polymorphism influence clinical outcomes of Thai osimertinib-treated non-small cell lung cancer patients
Article in Frontiers in Pharmacology (November 2023)
The most recent citing publications are shown below. View all 3 publications that cite this research output on Dimensions.
Genetic Polymorphisms in CYP2C19 Cause Changes in Plasma Levels and Adverse Reactions to Anlotinib in Chinese Patients With Lung Cancer
Article in Frontiers in Pharmacology (June 2022)
Clinical implications of germline variations for treatment outcome and drug resistance for small molecule kinase inhibitors in patients with non-small cell lung cancer
Article in Drug Resistance Updates (April 2022)